D
Absci Corporation ABSI
$2.88 -$0.08-2.70% NASDAQ
Recommendation
Prev Close
$2.88
Volume
37,293
Avg Vol (90D)
4,846,389
Market Cap
$367.37M
Dividend & Yield
--
52-Week Range
$2.01 - $6.33
P/E (TTM)
--
EPS (TTM)
-$0.9243
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Which Healthcare Stock Is the Best Buy Right Now?
3/31/2025 - MarketBeat
Schonfeld Strategic Advisors LLC Lowers Stake in Absci Co. (NASDAQ:ABSI)
5/17/2025 - MarketBeat
Dimensional Fund Advisors LP Acquires 241,779 Shares of Absci Co. (NASDAQ:ABSI)
5/17/2025 - MarketBeat
Absci's (ABSI) "Buy" Rating Reaffirmed at Needham & Company LLC
5/16/2025 - MarketBeat
Absci Corp's Earnings Call: A Promising Outlook
5/16/2025 - TipRanks Financial Blog
Absci Corp (ABSI) Q1 2025 Earnings Call Highlights: Transition to Clinical Stage and Strong ...
5/14/2025 - GuruFocus
Q1 2025 Absci Corp Earnings Call Transcript
5/14/2025 - GuruFocus
Absci (ABSI) Launches First Human Trial for ABS-101
5/14/2025 - GuruFocus
Absci signals expanded clinical pipeline with ABS-101 in Phase I and ABS-201 targeting early 2026 trial
5/14/2025 - SeekingAlpha.com: All News
Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript
5/14/2025 - Seeking Alpha: Transcripts
Absci Corporation (ABSI) Q1 2025 Earnings Call Transcript
5/14/2025 - SeekingAlpha
This AI-designed drug for IBD was just given to human subjects for the first time
5/13/2025 - ZDNet Latest News
Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates
5/13/2025 - Zacks Investment Research
Absci (ABSI) Initiates Phase 1 Study of AI-Designed Antibody ABS-101 ABSI Stock News
5/13/2025 - GuruFocus
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
5/13/2025 - GuruFocus
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential ...
5/13/2025 - GuruFocus
Absci Corp Q1 2025 Earnings: EPS Beats Estimates at -$0.21, Revenue Misses at $1.2 Million
5/13/2025 - GuruFocus
AbSci (ABSI) Anticipates Significant Post-Earnings Movement ABSI Stock News
5/13/2025 - GuruFocus
Absci reports first participants dosed in Phase 1 ABS-101 trial
5/13/2025 - The Fly
Absci reports Q1 EPS (21c), consensus (22c)
5/13/2025 - TipRanks Financial Blog
Absci reports Q1 EPS (21c), consensus (22c)
5/13/2025 - The Fly
Absci Reports Business Updates and First Quarter 2025 Financial and Operating Results
5/13/2025 - Globe Newswire
Absci Announces First Participants Dosed in Phase 1 Clinical Trial of ABS-101, a Potential Best-In-Class anti-TL1A Antibody for the Treatment of Inflammatory Bowel Disease
5/13/2025 - Globe Newswire
AbSci Corp options imply 13.4% move in share price post-earnings
5/13/2025 - TipRanks Financial Blog
AbSci Corp options imply 13.4% move in share price post-earnings
5/13/2025 - The Fly
Income Statement
Total Revenue (TTM)
$4.82M
EBITDA (TTM)
-$98.67M
EBIT (TTM)
-$111.72M
Net Income (TTM)
-$107.48M
Balance Sheet
Total Assets (Q)
$232.45M
Total Debt (Q)
$8.92M
Total Liabilities (Q)
$33.65M
Book Value Per Share (Q)
$1.56
Cash Flow
Cash from Operations (TTM)
-$76.38M
Cash from Investing (TTM)
$20.06M
Cash from Financing (TTM)
$44.14M
Net Change in Cash (TTM)
-$12.18M
Filings
Filing Date
Tuesday, May 13, 2025
Period Date
Monday, March 31, 2025
Next Filing
Week of Aug 11 and 15 (est)
Price History
Loading...
Beta
2.38
7-Day Total Return
2.86%
30-Day Total Return
26.32%
60-Day Total Return
-41.94%
90-Day Total Return
-6.19%
Year to Date Total Return
6.27%
1-Year Total Return
-37.59%
2-Year Total Return
139.00%
3-Year Total Return
-23.40%
5-Year Total Return
--
52-week Low
Apr 04, 2025 - $2.01
52-week High
Feb 18, 2025 - $6.33
Valuation
Market Cap
$367.37M - Small Cap
Enterprise Value
$242.30M
Price/Sales (TTM)
74.61
Price/Book (Q)
1.85
Dividends and Shares
Shares Outstanding
124.46M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.absci.com
Phone Number
360 949 1041
Address
18105 SE Mill Plain Boulevard
Vancouver, WA 98683
Country
United States
Year Founded
2011
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Absci Corporation operates as a data-first generative artificial intelligence (AI) drug creation company in the United States. The company combines AI with scalable wet lab technologies to design... more
NASDAQ 05/16/2025 4:00PM Eastern Quotes delayed